In silico methods, or using computer modelling and simulation (CM&S), is utilised to amplify and accelerate the design, development, testing and regulatory approval of new medical treatments. To achieve this goal, the healthcare community needs a clear and harmonised regulatory framework to ensure the necessary credibility of this approach for maximising patient safety while accelerating medical innovation.
In the last decade, policy makers from around the world have paid an increasing attention to this technology having the promise to accelerate medical innovation and make health care safer, more affordable, more effective and more efficient for their citizens. In addition, adopting this technology, widely used in other industries (such as aerospace, automotive or hightech among others), is also giving a clear competitive advantage to the industrial healthcare community operating in their region.
In leading regions, policy makers have facilitated research funding and built the legislative framework to validate computational models and encouraged their usage in faster regulatory approval process without compromising with safety and effectiveness for the benefits of local citizen and industries.
NEWS
Avicenna at FDA / MDIC Event in Washington, April 16 - 17
Many representatives of the Avicenna Alliance networked with good friends and in silico thought leaders from around the world at the FDA / MDIC symposium on Computation Modeling & Simulation in Washington.
The European Parliament voted the reform of General Pharmaceutical Legislation (GPL)
On April 10, the European Parliament overwhelmingly backed the reform of General Pharmaceutical Legislation (GPL), marking a pivotal moment in healthcare regulation. With a resounding majority, both the Directive and Regulation were embraced, reflecting a collaborative effort within the ENVI committee.
The Avicenna Alliance warmly welcomes Tox By Design into its esteemed ranks!
Tox by Design is a prominent European toxicological expertise firm specializing in conducting toxicological Risk Assessments (RAs) for various industries such as biotech, pharmaceuticals, cosmetics, medical devices, and API synthesis.